Click Chemistry

Fimepinostat is a dual PI3K and HDAC inhibitor. Studies have shown Fimepinostat is able to enhance antitumor activity when combined with standard of care agents to inhibits cell growth in a panel of colon, pancreatic, non-small cell lung cancer (NSCLC), and multiple myeloma cells. Reagent grade, for research purpose.

LMK-235 catalyze the hydrolytic removal of acetyl groups from histone lysine residues. LMK-235 is an HDAC4 and HDAC5 inhibitor that has shown to have enhanced cytotoxic effects against the human cancer cell lines A2780, Cal27, Kyse510, and MDA-MB231. Reagent grade, for research purpose.

Mocetinostat is a benzamide histone deacetylase (HDAC) inhibitor. Mocetinostat is currently being studied as a treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia. Reagent grade, for research purpose.

Pracinostat is a potent and orally active histone deacetylase (HDAC) inhibitor and also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity. The selectivity of Pracinostat for tumor tissues makes it a promising therapeutic candidate for use in patients with advanced solid malignancies. Reagent grade, for research purpose.

Quisinostat HCl is an inhibitor of histone deacetylase (HDAC) enzymes. Quisinostat HCl disrupts the HAT-dependent transcriptional repression complex in the nucleus to promote expression of genes involved in cellular proliferation. Quisinostat HCl is also an inhibitor of catalytic subunit of DNA polymerase δ, which is required for replication at the site of DNA damage induced by radiation or chemotherapeutic agents. Reagent grade, for research purpose.

Rocilinostat is a specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Reagent grade, for research purpose.

Romidepsin is a natural bicyclic depsipeptide that binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins. Reagent grade, for research purpose.

Splitomicin is a small-molecule inhibitor that binds to the protein SIRT1 and inhibits its activity. Splitomicin has been shown to have therapeutic potential in autoimmune diseases, such as type 1 diabetes, by preventing the production of inflammatory molecules. Splitomicin also has cardiac effects, which include inhibition of the transcriptional regulator Nrf2 and erythrocyte membrane fluidity. Reagent grade, for research purpose.

TMP269 is a small molecule inhibitor that is a selective class IIa histone deacetylase (HDAC) inhibitor via a non chelating zinc-binding group. TMP269 has been shown to have antiproliferative effects on human bladder cancer cells. TMP269 inhibits the biological function of the growth factor and homologous protein, which are transcriptional regulators of urothelial carcinoma. Reagent grade, for research purpose.